Some would have you believe that finding growth in this market right now with so much global turmoil is an impossible task. That you would have to overturn every rock and then wish on a falling star to find just a few names. Well, investors should save their falling star moments for better wishes.
One way to indentify firms that are potentially experiencing real growth is by reviewing their 1-Year Fiscal Growth Rate. This growth rate covers multiple periods and helps average out any potentially “hot” quarters. While this metric won’t guarantee future growth for a firm, it will point out which firms are experiencing strong growth despite global economic turmoil.
We ran a screen for firms that have retraced at least 10% from their 52-week high and illustrate strong top line growth (1-Year Fiscal Revenue Growth Rate>20%). From this narrowed pool we then screened for firms that were flush with cash (Current Ratio>3).
The list is ranked from lowest to highest by 1-Year Fiscal Revenue Growth Rate.
1. Momenta Pharmaceuticals, Inc. (MNTA)
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | $793M |
Beta | 1.27 |
The company specializes in the structural analysis of complex mixture drugs, drug products, and development of novel drugs. The firm's 1-year fiscal revenue growth rate is 476.68%. MNTA is 26.24% below the 52-week high. The firm's current ratio is 25.80. The short interest is 15.60% as of 08/15/2011.Given the short interest, this could be a short favorite or potentially a great short squeeze.
2. InterMune, Inc. (ITMN)
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | $1,331M |
Beta | 2.45 |
The company develops and sells innovative therapies in hepatology and pulmonology. The firm’s 1-year fiscal revenue growth rate is 432.43%. ITMN is 57.65% below the 52-week high. The firm’s current ratio is 8.26. The short interest is 10.60% as of 08/15/2011. Given the short interest, this could be a short favorite or potentially a great short squeeze.
3. AMAG Pharmaceuticals, Inc. (AMAG)
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | $295M |
Beta | 0.64 |
The Company develops super paramagnetic iron oxide nanoparticles used in pharma products. The firm’s 1-Year fiscal revenue growth rate is 285.64%. AMAG is 52.78% below the 52-week high. The firm’s current ratio is 6.92. The short interest is 0.64 as of 08/15/2011.
4. Veeco Instruments Inc (VECO)
Sector | Technology |
Industry | Semiconductor Equipment & Materials |
Market Cap | $1,405M |
Beta | 2.78 |
The company designs, manufactures, and sells primarily used by manufacturers in data storage, the semiconductor industry, and other industries. The firm’s 1-year fiscal revenue growth rate is 230.45%. VECO is 40.68% below the 52-week high. The firm’s current ratio is 3.55. The short interest is 35.00% as of 08/15/2011. Given the short interest, this could be a short favorite or potentially a great short squeeze.
5. JA Solar Holdings Co., ADR (JASO)
Sector | Technology |
Industry | Solar |
Market Cap | $ 539M |
Beta | 3.03 |
Analyst Sentiment |
The Company manufactures solar cells in China. The firm’s 1-year fiscal revenue growth rate is 211.25%. JASO is 69.04% below the 52-week high. The firm’s Current Ratio is 3.20. The short interest is N/A as of 08/15/2011.
6. Advanced Energy Industries (AEIS)
Sector | Technology |
Industry | Electronic Components |
Market Cap | $ 395M |
Beta | 1.95 |
The company develops and manufactures power conversion and control systems and gas flow control devices for plasma related equipment. The firm’s 1-year fiscal revenue growth rate is 183.86%. AEIS is 46.76% below the 52-week high. The firm’s current ratio is 4.13. The short interest is 6.60% as of 08/15/2011.
7. Brooks Automation, Inc. (BRKS)
Sector | Technology |
Industry | Semiconductor Equipment & Materials |
Market Cap | $ 565M |
Beta | 1.66 |
The company supplies tech products and solutions for the semiconductor industry. The firm’s 1-year fiscal revenue growth rate is 171.13%. BRKS is 41.40% below the 52-week high. The firm’s current ratio is 4.27. The short interest is 4.00% as of 08/15/2011.
8. Impax Laboratories, Inc. (IPXL)
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | $1,122M |
Beta | 0.49 |
The company manufactures and sells bioequivalent pharmaceutical products. The firm’s 1-year fiscal revenue growth rate is 145.39%. IXPL is 40.63% below the 52-week high. The firm’s current ratio is 3.88. The short interest is 7.80% as of 08/15/2011.
9. Nektar Therapeutics, Inc. (NKTR)
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | $ 573M |
Beta | 0.49 |
The company develops novel medicines. The firm’s 1-year fiscal revenue growth rate is 121.10%. NKTR is 68.80% below the 52-Week High. The firm’s current ratio is 6.35. The short interest is 12.30% as of 08/15/2011. Given the short interest, this could be a short favorite or potentially a great short squeeze.
10. MKS Instruments, Inc. (MKSI)
Sector | Industrials |
Industry | Diversified Industrials |
Market Cap | $ 1,172M |
Beta | 1.35 |
The company provides components and processes control solutions that measure, control, power and monitor critical parameters for various industries. The firm’s 1-year fiscal revenue growth rate is 117.25%. MKSI IS 34.00% below the 52-week high. The firm’s current ratio is 8.33. The short interest is 4.70% as of 08/15/2011.
We hope this list helps as investors do their own due diligence on companies with bullish trends that have strong top line growth.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
